Senators Call on FDA to Act Against Misleading Weight-Loss Drug Commercials
By Stephanie Brown HealthDay Reporter
WEDNESDAY, Feb. 12, 2025 -- Commercials run by the telehealth company Hims & Hers have been placed under the microscope as lawmakers are calling out advertisement of prescription of injectable weight-loss drugs without disclosing safety and risk information.
In a currently running advertisement, the direct-to-consumer telehealth company promotes its ability to prescribe and dispense glucagon-like peptide-1 (GLP-1) receptor agonist medications to patients. The commercials include claims about the effectiveness of the weight-loss drugs, as well as imagery of an injection pen not unlike an existing brand-name medication.
Last week, ahead of the commercial running during Super Bowl LIX, U.S. Senate Democratic Whip Dick Durbin (D-Ill.) and Sen. Roger Marshall, M.D. (R-Kan.) sent a letter to the U.S. Food and Drug Administration to alert the agency to the advertisement.
"An upcoming Super Bowl advertisement, which has been publicly posted online, appears to showcase a company's ability to prescribe and dispense GLP-1 medications to patients," the letter states. "However, nowhere in this promotion is there any side effect disclosure, risk, or safety information as would be typically required in a pharmaceutical advertisement. Further, for only three seconds during the minute-long commercial does the screen flash in small, barely legible font, that these products are not FDA-approved."
The commercial appears to be taking advantage of a perceived loophole in federal law regarding promotions of compounded drugs by telehealth companies, according to a press release from Sen. Durbin. However, Sens. Durbin and Marshal contend that this advertisement does fall under FDA jurisdiction.
"To the extent this falls within a regulatory loophole for the FDA's authorities, we plan to soon introduce bipartisan legislation to close this gap, so that patients are not deceived by advertisements that glaringly omit critical safety and side effect information," the letter concludes. "But, we believe FDA may already have the authority to take enforcement action against marketing that may mislead patients about this company's products."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted February 2025
Read this next
Diabetic Women Should Be Asked About Desire For Kids At Every Doctor's Visit, Guidelines Say
FRIDAY, July 18, 2025 — Doctors should ask diabetic women at every visit about their intention to have a child, to make sure they get the appropriate care prior to...
Belly Fat Increases Stress Incontinence Risk
THURSDAY, July 17, 2025 — Middle-aged women with more belly fat have a higher risk for stress urinary incontinence, a recent study says. Fat around the waist and visceral...
Experts Recommend Healthy Lifestyle Changes Alongside GLP-1 Drug Use
WEDNESDAY, July 16, 2025 — GLP-1 weight-loss drugs like Ozempic and Zepbound are so effective it might seem that a person can lose weight without doing anything at all. But...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.